NewsNews

Science news

  1. 1

    Japan launches MMX mission to Mars moon Phobos to return samples

    Japan's Mars Moons Exploration (MMX) spacecraft launched toward Mars to collect material from Phobos and bring it back to Earth, which would be the first sample returned from Mars or its moons. The Japanese Space Agency (JAXA) leads the mission, which is scheduled to reach Phobos in August 2027 and return the sample to Australia's Woomera desert in 2031. A small rover, Idefix, will scout the surface before a lander collects about 10 grams of material. Scientists hope the sample will settle whether Mars's moons were formed from a giant impact or captured asteroids. The Associated Press reported the mission's cost at $578 million. Mars Sample Return, a NASA and ESA mission, has been effectively cancelled after US Congress halted its funding.

    Key facts

    • The MMX spacecraft launched from Tanegashima Island, Japan, on October 19 toward Mars.
    • The spacecraft is due to reach Phobos in August 2027 and return a sample in 2031.
    • The lander aims to collect at least 10 grams of material from Phobos.
    • Scientists are debating whether Phobos formed from a giant impact or a captured asteroid.
    • The $578 million mission is led by the Japanese Space Agency JAXA.

    Commentary

    The launch is the predictable part; what matters is that the mission's payoff depends on a tiny 10-gram sample reaching labs, while Mars Sample Return's cancellation leaves no funded route for Perseverance's canisters. Japan may therefore become the first to bring material back from the Martian system, a position the articles describe as a race with China's 2031 target. Readers should watch the 2028-2029 landing, since the sample's value rests on it.

    Sources: BBC, WGN Radio 720, Science News

  2. 2

    Karl Deisseroth, Peter Hegemann and Georg Nagel win 2026 Nobel Prize for controlling brain cells with light

    Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded this year's Nobel Prize in physiology or medicine for their research into light-gated ion channels and optogenetics. Hegemann, at Humboldt University of Berlin, and Nagel, at the University of Würzburg, began by studying how the single-celled alga Chlamydomonas senses light, finding that a protein called channelrhodopsin opens a passage in the cell membrane when light changes the shape of a molecule within it. Deisseroth, a psychiatrist and bioengineer at Stanford University, helped apply this to nerve cells, which can be switched on by delivering the channelrhodopsin gene and shining light into the brain. Scientists now use optogenetics to study how specific nerve cells affect memory, sleep and movement, and it is in early-stage clinical trials for retinal degeneration.

    Key facts

    • Deisseroth, Hegemann and Nagel were honored for research into light-gated ion channels and optogenetics.
    • Channelrhodopsin opens a passage in the cell membrane when light changes the shape of retinaldehyde.
    • Optogenetics is in early-stage clinical trials for people with retinal degeneration.
    • In a 2012 MIT experiment, mice reactivated by light froze as if remembering a shock.
    • Researchers are investigating optogenetics as a possible treatment for Parkinson's and epilepsy.

    Commentary

    The headline event is the predictable part; the less obvious point is that the prize rewards a question about algae swimming, which had no clear practical aim. Optogenetics shows how basic curiosity about how cells sense their surroundings can later become a tool for studying and perhaps treating the brain. Its future medical value remains unproven and depends on trials still at an early stage.

    Sources: Science Daily

  3. 3

    US Researchers Leave Country Over Funding Cuts and Political Pressure on Science

    Scientists are leaving the United States for foreign universities, citing delayed federal grants, fears about future funding and political influence over which projects get funded under the Trump administration. Foreign universities and countries including Canada, France, Belgium and Finland have adopted recruitment programs promising stable funding and academic freedom. Halley Froehlich moved from the University of California, Santa Barbara to the University of Helsinki, and Christine Stawitz left NOAA for the University of Birmingham, while James Letts and Maria Maldonado moved to Monash University in Australia. The Association of American Universities' Tobin Smith said nearly every university research vice president can name lost top faculty, while White House spokesperson Liz Huston said Trump is ending waste and committed to funding real science. Scientists warn the effects could take a decade or longer to fully emerge.

    Key facts

    • More than half of American states have lost scientists to recruitment programs in other countries, per an April Business for Federal Research Funding Coalition report.
    • Physics Ph.D. graduates in 2025 left the U.S. at the highest rate in 30 years, according to the American Institute of Physics.
    • The Trump administration has cut or frozen up to $174 billion in federal grants since the second term began, per a tracking tool.
    • Major research institutions accepted 15% fewer applicants for fall 2026 doctoral programs than last year, according to AAU data.
    • A proposed Office of Management and Budget rule could give political appointees more control over future funding; Congress delayed a final decision until December.

    Commentary

    The departures are the predictable part; the less visible cost is reputational, which Christine Stawitz says is hard to quantify yet damaging. Recruiting countries are gaining talent that took the U.S. decades to build, and the pending OMB rule suggests political control over grants may deepen rather than ease. Readers should watch the December decision and fall 2026 admissions, since the doctoral pipeline is where losses will compound.

    Sources: AP News

  4. 4

    IPCC scientists vow to keep working on climate reports despite political deadlock

    Scientists will keep working on the next flagship Intergovernmental Panel on Climate Change reports, despite a political row that led to the latest session being suspended on Friday evening without agreement. The dispute centres on the timeline for the three key parts of the AR7 assessment, specifically whether they should all be published before the UN's next Global Stocktake, due for completion in late 2028. The disagreement has persisted since early 2024. Officials and scientists expressed disappointment over the weekend, and some delegates from developing countries and small island states left the week-long meeting in Ethiopia early to catch flights home.

    Key facts

    • The latest IPCC session was suspended Friday evening without agreement on the AR7 timeline.
    • The AR7 publication-timing dispute has persisted since early 2024.
    • The core question is whether all three AR7 parts publish before the Global Stocktake concludes.
    • The UN Global Stocktake is due to be completed in late 2028.
    • Some delegates from developing countries and small island states left Ethiopia early to catch flights.

    Commentary

    The sticking point is sequencing rather than science: whether AR7 lands before the Global Stocktake decides how far its findings can shape that process. Delegates from poorer nations leaving early suggests those with the least room to wait bear the cost of the stalemate.

    Sources: Climate Home News

  5. 5

    Restoring sleep improves Alzheimer's symptoms in mouse study without clearing brain plaques

    Researchers at the University of Kentucky reported that microglia, the brain's immune cells, contribute to sleep disruption in mice with Alzheimer's-like brain changes. Led by Shannon L. Macauley and first author Nicholas J. Constantino, the team found that temporarily depleting about 87% of microglia using the drug Pexidartinib (PLX3397) restored more than two hours of sleep per day. The mice also gained longer periods of restorative NREM sleep, and these improvements occurred even though amyloid plaques remained present. Macauley called the findings "paradigm-shifting," while the researchers cautioned that the experiments were conducted only in mice and that depleting immune cells is not a practical treatment. The team is now exploring whether adjusting microglial activity, including with the existing drugs Metformin and Stiripentol, could achieve similar benefits.

    Key facts

    • Mice regained more than two hours of sleep per day after microglia were temporarily depleted.
    • Pexidartinib depleted about 87% of microglia in mice fed the drug for 14 days.
    • Amyloid plaques remained present, yet the mice's sleep improved substantially.
    • Sleep disruption appeared by six months and did not worsen by 18 months despite doubled plaque burden.
    • The study was conducted in mice, and the researchers have not shown the same benefits in people.

    Commentary

    The plaques were not the main culprit; the immune response to them was, and that reframes where treatment should aim. Because sleep loss plateaued early while plaques kept accumulating, intervention may matter most in the disease's early stages. The unresolved question is whether dampening microglial activity, rather than destroying those cells, can work in people, a test the mouse data cannot answer.

    Sources: Science Daily

Today's video

Also posted to: